FY2025 · ended Dec 31, 2025 · Revenue $4.25B, -2.8% YoY · Filed Feb 26, 2026
Perrigo Company plc (PRGO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.3 billion and a net loss of $1.4 billion. Free cash flow was $145.1 million. As of Sep 26, 2026 it held $436.6 million in cash and investments and $3.5 billion in total debt.
Revenue (TTM)
$4.09B
-4.5% vs year-ago TTM
Net income (TTM)
$-1.77B
-3316.4% vs year-ago TTM
Operating cash flow (TTM)
$240.60M
-36.0% vs year-ago TTM
Free cash flow (TTM)
$168.20M
-38.0% vs year-ago TTM
EPS (TTM)
$-12.76
-3311.3% vs year-ago TTM
Dividend per share
$1.16
+5.5% vs prior year
Shares outstanding
137.65M
+0.9% vs prior year
Net cash
$-3.03B
as of Sep 26, 2026
Operating margin
-39.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRGO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1585364
- Former names
- PERRIGO Co Ltd (until Nov 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.4B | $4.7B | $4.5B | $4.1B |
| Operating income | -$1.1B | $112.9M | $151.9M | $78.9M | $410.4M |
| Net income | -$1.4B | -$171.8M | -$12.7M | -$140.6M | -$68.9M |
| Diluted EPS | -$10.29 | -$1.25 | -$0.09 | -$1.04 | -$0.52 |
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M |
| Free cash flow | $145.1M | $244.6M | $303.8M | $210.9M | $4.2M |
| Total assets | $8.5B | $9.6B | $10.8B | $11.0B | $10.4B |
| Total liabilities | $5.6B | $5.3B | $6.0B | $6.2B | $5.3B |
| Stockholders' equity | $2.9B | $4.3B | $4.8B | $4.8B | $5.2B |
| Cash and investments | $531.6M | $558.8M | $751.3M | $600.7M | $1.9B |
| Total debt | $3.8B | $3.8B | $4.3B | $4.3B | $3.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 6, 2026 | Jun 7, 2026 |
All 1003 Perrigo Company plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.